Last $0.0022 USD
Change Today 0.00 / 0.00%
Volume 0.0
IMBI On Other Exchanges
Symbol
Exchange
OTC US
As of 4:30 PM 03/26/14 All times are local (Market data is delayed by at least 15 minutes).

immunobiotics inc (IMBI) Snapshot

Open
--
Previous Close
$0.0022
Day High
--
Day Low
--
52 Week High
01/15/14 - $0.03
52 Week Low
03/26/14 - $0.0022
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
$-0.03
Shares Outstanding
23.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNOBIOTICS INC (IMBI)

Related News

No related news articles were found.

immunobiotics inc (IMBI) Related Businessweek News

No Related Businessweek News Found

immunobiotics inc (IMBI) Details

ImmunoBiotics, Inc., a development stage company, engages in licensing the manufacture, distribution, and sale of nutraceutical products that are made of naturally occurring dietary substances. It licenses LutiMax line of products, including LutiMax 10mg tablets, LutiMax 100mg Lozenges, and LutiSyn Capsules for human consumption and a powder for canine consumption; and LutiSport line of products comprising a lozenge for human consumption, as well as a powder for canine consumption. The company was formerly known as Multinational Merger Corporation and changed its name to ImmunoBiotics, Inc. in August 2007. ImmunoBiotics, Inc. was founded in 2004 and is based in San Clemente, California.

1 Employees
Last Reported Date: 04/15/10
Founded in 2004

immunobiotics inc (IMBI) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: --
Chief Financial Officer, Vice President, Trea...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

immunobiotics inc (IMBI) Key Developments

SEC Orders Hearings On Registration Suspension Or Revocation Against ImmunoBiotics, Inc. For Failure To Make Required Periodic Filings

Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of ImmunoBiotics, Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMBI:US $0.00 USD 0.00

IMBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMBI.
View Industry Companies
 

Industry Analysis

IMBI

Industry Average

Valuation IMBI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOBIOTICS INC, please visit www.immunobiotics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.